Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

OBJECTIVE: This study aimed to report end-of-study results on efficacy and safety of secukinumab 150 mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (NCT01863732)). METHODS: After the 2-year core trial, 274 patients receiving subcutaneous secukinumab 150 or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Baraliakos, Xenofon, Braun, Juergen, Deodhar, Atul, Poddubnyy, Denis, Kivitz, Alan, Tahir, Hasan, Van den Bosch, Filip, Delicha, Evie-Maria, Talloczy, Zsolt, Fierlinger, Anke
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Spondyloarthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744073/
https://ncbi.nlm.nih.gov/pubmed/31565244
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2019-001005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados